Home > Insider Trading > Filing (0001209191-10-042615)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
858803	Avanir Pharmaceuticals Inc.	AVNR	Pharmaceutical Preparations (2834)	330314804

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1280154	Christine Ocampo	101 Enterprise, Suite 300 Aliso Viejo CA 92656	Vice President, Finance	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-08-11	16,250	$1.20	58,232	No	4	M	Direct
Common Stock	Acquisiton	2010-08-11	12,000	$0.88	70,232	No	4	M	Direct
Common Stock	Disposition	2010-08-11	15,669	$3.11	54,563	No	4	S	Direct
Common Stock	Disposition	2010-08-11	12,581	$3.10	41,982	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2010-08-11	16,250	$0.00	16,250	$1.20
Common Stock	Stock Option (right to buy)	Disposition	2010-08-11	12,000	$0.00	12,000	$0.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,750		2017-03-29	No	4	M	Direct
36,000		2018-07-25	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,900	Indirect	By spouse

Footnotes

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
The proceeds from such sales were used in part to pay required tax withholdings due upon vesting of restricted stock units previously granted to the Reporting Person.
These shares are held by the Reporting Person's spouse, which are deemed beneficially owned by the Reporting Person.
Options vest in accordance with the following schedule: 25% of the shares on the first anniversary of the date of grant, which was March 29, 2007, and with respect to an additional 6.25% of the Shares quarterly thereafter for the next three years.
The options to purchase 48,000 shares of Common Stock were granted upon the achievement of certain performance goals relating to the clinical development of Zenvia. Upon achievement of the performance goals, the option vested with respect to 6.25% of the underlying shares and will continue to vest with respect to 6.25% of the underlying shares on a quarterly basis over 15 quarters.